• Gilead to acquire breast cancer drugmaker Immunomedics for $21B

    12 days ago - By MedCity News

    The deal marks Gilead's latest big-ticket move into oncology this year, with Immunomedics' Trodelvy anticipated to reach $4 billion in peak sales. However, at least one analyst suggested Gilead may have overpaid.
    Read more ...

     

  • Merck, Seattle Genetics form partnerships worth $4.5B focused on two cancer drugs

    Merck, Seattle Genetics form partnerships worth $4.5B focused on two cancer drugs

    12 days ago - By MedCity News

    One deal is a $4.2 billion development and commercialization partnership focused on ladiratuzumab vedotin, while the other would expand the reach of the breast cancer drug Tukysa.
    Read more ...